Affiliations: [a] Faculty of Medicine and Dentistry, School of Clinical Sciences, Dementia Research Group, University of Bristol, John James Laboratories, Frenchay Hospital, Bristol, UK | [b] Faculty of Medicine and Dentistry, School of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, UK
Correspondence:
[*]
Correspondence to: Patrick G. Kehoe, School of Clinical Sciences, Faculty of Medicine and Dentistry, University of Bristol, John James Laboratories, Frenchay Hospital, Bristol, BS16 1LE, UK. Tel.: +44 (0) 117 340 6607; Fax: +44 (0) 117 340 6665; E-mail: Patrick.Kehoe@bristol.ac.uk.
Abstract: We investigated whether angiotensin II receptor blockers and angiotensin converting enzyme inhibitors were associated with risk of mortality or inpatient hospitalization for patients with dementia compared to other antihypertensive medications. We extracted a clinical cohort of 6,290 patients with dementia from the United Kingdom General Practice Research Database, prescribed antihypertensive medication at diagnosis of dementia with around 10 years follow-up. Using survival analysis we estimated associations of exposure to antihypertensive medication with subsequent hospitalization and mortality risk, stratified by dementia type (Alzheimer's disease, vascular and other dementias). Angiotensin converting enzyme inhibitors (but not angiotensin II receptor blockers) were associated with an increased risk of mortality in patients with Alzheimer's disease (adjusted hazard ratio: 1.19; 95% CI 1.07, 1.33, p = 0.002), but no convincing evidence of increased hospitalization. Angiotensin II receptor blockers were inversely associated with hospitalization for any form of dementia, but after adjustment for covariates, these associations became consistent with chance. Further evidence is required to either support or refute the observation that exposure to angiotensin converting enzyme inhibitors in patients with dementia is associated with increased mortality.
